$30.890
-0.306 (-0.99%)收盤時
STOK 資訊
STOK 事件
Stoke Therapeutics and Biogen Present Epilepsy Data in Athens
Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of data at the 16th European Epilepsy Congress September 5-9 in Athens. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. The global, pivotal Phase 3 EMPEROR study is underway to evaluate the safety and efficacy of zorevunersen, and results are anticipated in 3Q27. Improvements in cognition and behavior were sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile. New exploratory sub-analyses show effects on the most severe seizure types, which are the leading risk factor for sudden unexpected death in epilepsy, as well as improvements in quality of life for patients treated with zorevunersen. Zorevunersen continues to be generally well tolerated, with some patients treated for more than 5 years in the Phase 1/2a and ongoing OLE studies. As of July 31, more than 930 doses have been administered.
Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer
Stoke Therapeutics announced that Thomas McCauley, Ph.D., has been appointed Chief Scientific Officer. McCauley most recently served as the President and Chief Executive Officer of Neptune Bio
Stoke Therapeutics Completes Enrollment of 162 Patients in EMPEROR Study
Stoke Therapeutics announced the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen. Stoke plans to initiate a rolling New Drug Application, NDA, submission to the U.S. Food and Drug Administration, FDA, in the first quarter of 2027. A Phase 3 data readout is anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the second half of 2027.
Company Reports Q1 Revenue of $6.23M
Reports Q1 revenue $6.23M, consensus $5.88M.
Stoke Therapeutics and Biogen Publish Zorevunersen Study Data
Stoke Therapeutics (STOK) and Biogen (BIIB) announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine, or NEJM. The publication includes results from two completed Phase 1/2a and ongoing open-label extension, or OLE, studies that demonstrate, for the first time, the potential for disease modification in people living with Dravet syndrome. These data showed substantial and durable reductions in seizures and improvements across multiple measures of cognition and behavior that began in the Phase 1/2a treatment period and continued through three additional years of treatment in the OLEs. The effects were shown in people treated with zorevunersen on top of standard of care anti-seizure medicines. The Phase 1/2a studies evaluated single and multiple doses of zorevunersen up to 70 mg with a primary endpoint of safety. Change in major motor seizure frequency was assessed as a secondary endpoint. Substantial reductions in seizures were observed among zorevunersen-treated patients in the Phase 1/2a studies and continued through three years of treatment in the OLEs. The most substantial reductions in seizure frequency were observed among patients treated with initial doses of 70 mg in the Phase 1/2a studies. Changes in neurodevelopment, functioning, clinical status and quality of life for all patients were assessed as additional endpoints in the OLEs using standard clinical assessments. Improvements in communication, motor skills, socialization, daily living and quality of life continued through three additional years of treatment. Zorevunersen has been generally well tolerated across the Phase 1/2a and OLE studies. Eighty-one patients received at least one dose of zorevunersen and were evaluated for safety, and more than 800 doses have been administered across these studies to date. The most common treatment-related adverse event was cerebrospinal fluid protein elevations with a higher incidence observed in the OLE studies. No related clinical manifestations have been observed, although one patient discontinued treatment due to elevated CSF protein levels. All serious adverse events were assessed to be unrelated to zorevunersen except in one patient who experienced suspected unexpected serious adverse reactions.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。